The stock of Xeris Biopharma Holdings Inc (NASDAQ: XERS) has increased by 6.80 when compared to last closing price of 4.40.Despite this, the company has seen a gain of 3.28% in its stock price over the last five trading days. businesswire.com reported 2025-06-03 that CHICAGO–(BUSINESS WIRE)–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. “We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achi.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
Company’s 36-month beta value is 0.72.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XERS is 147.60M, and currently, short sellers hold a 11.92% ratio of that floaft. The average trading volume of XERS on June 17, 2025 was 2.80M shares.
XERS’s Market Performance
The stock of Xeris Biopharma Holdings Inc (XERS) has seen a 3.28% increase in the past week, with a -3.70% drop in the past month, and a -9.98% fall in the past quarter. The volatility ratio for the week is 2.34%, and the volatility levels for the past 30 days are at 3.15% for XERS. The simple moving average for the last 20 days is 0.25% for XERS’s stock, with a simple moving average of 24.25% for the last 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Piper Sandler repeating the rating for XERS by listing it as a “Neutral.” The predicted price for XERS in the upcoming period, according to Piper Sandler is $3 based on the research report published on November 11, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see XERS reach a price target of $5. The rating they have provided for XERS stocks is “Outperform” according to the report published on March 28th, 2024.
Craig Hallum gave a rating of “Buy” to XERS, setting the target price at $4.50 in the report published on August 28th of the previous year.
XERS Trading at 3.28% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.58% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from McCulloch Kevin, who purchase 25,000 shares at the price of $4.38 back on Jun 13 ’25. After this action, McCulloch Kevin now owns 1,708,585 shares of Xeris Biopharma Holdings Inc, valued at $109,475 using the latest closing price.
Fairley Ricki Louise, the Director of Xeris Biopharma Holdings Inc, proposed sale 56,667 shares at $4.90 during a trade that took place back on May 09 ’25, which means that Fairley Ricki Louise is holding shares at $277,668 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.81 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.2. The total capital return value is set at -0.1. Equity return is now at value -617.16, with -13.83 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at -7.65. The interest coverage ratio of the stock is -0.73.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -24.29. When we switch over and look at the enterprise to sales, we see a ratio of 4.32. The receivables turnover for the company is 4.8for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
In a nutshell, Xeris Biopharma Holdings Inc (XERS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
